Login / Signup

Tocilizumab for juvenile idiopathic arthritis: a single-center case series.

Evrim Kargın ÇakıcıSemanur OzdelDoğan ŞimşekÖzlem AydoğEvrim Kargın CakıcıGökçe Gür CanTulin GungorMehmet Bülbül
Published in: Sao Paulo medical journal = Revista paulista de medicina (2020)
Tocilizumab therapy should be considered for treating patients with diagnoses of pJIA or sJIA who are resistant to non-biological DMARDs and/or other biological therapies.
Keyphrases
  • juvenile idiopathic arthritis
  • disease activity
  • rheumatoid arthritis patients
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • stem cells
  • cell therapy
  • replacement therapy